🤖 GLOBAL HEALTH OPTIMIZATION AGENT v3.0

🔬 Current Disease Focus:

Task Progress: 0%

👥 Active Problem Solvers

🌍 Experts collaborating globally

⚡ Current Task Assignment

🧬 Genetic Analysis

🔄 Matching experts to specific tasks

📊 Resource Allocation by Research Phase:

📚 Data Analysis

🧪 Experimental Design

🔬 Clinical Trials

💊 Treatment Development

Trial Search

Current Search Criteria:

Intervention: BI 207127 + faldaprevir

Found 13 matching trials

Effect of BI 207127 + Faldaprevir on Blood Levels of Oral Contraceptives Containing Ethinylestradiol and Levonorgestrel

PHASE1

Investigate the effect of multiple oral doses of BI 207127 + faldaprevir (F...

Status

Terminated

Location

1241.31.2 Boehringer Ingelheim Investigational Site

Start Date

2013-11

Trial ID

NCT01941615

Treatments Being Tested

faldaprevir Microgynon®BI 207127

This Trial Evaluates Safety, Pharmacokinetic Profile and Anti-viral Response of BI 207127 and BI 201335 for Patients With Chronic Hepatitis C

PHASE2

The objective of this trial is to investigate tolerability, safety, pharmac...

Status

Completed

Location

1241.25.002 Boehringer Ingelheim Investigational Site

Start Date

2012-02

Trial ID

NCT01528735

Treatments Being Tested

BI 207127 NA peginterferon Ribavirin Ribavirin BI 207127 NA BI 201335 NA BI 201335 NA peginterferon

Open Label Trial to Compare BI 207127 to Telaprevir in HCV Patients

PHASE3

The aim of this trial is to evaluate efficacy and safety of treatment with ...

Status

Withdrawn

Location

1241.37.61002 Boehringer Ingelheim Investigational Site

Start Date

2013-05

Trial ID

NCT01858961

Treatments Being Tested

BI 201335 ribavirin BI 207127 Telaprevir ribavirin Pegylated Interferon

BI 207127 / Faldaprevir Combination Therapy in Hepatic Impairment (Child-Pugh B) Patients With Genotype 1b Chronic Hepatitis C Infection: HCVerso3

PHASE2

To assess the pharmacokenetic characteristics of 600 mg BID BI 207127 / 120...

Status

Completed

Location

1241.30.10003 Boehringer Ingelheim Investigational Site

Start Date

2013-04

Trial ID

NCT01830127

Treatments Being Tested

Ribavirin BI 207127 high dose Faldaprevir Ribavirin BI 207127 low dose Faldaprevir

IFN-free Combination Therapy in HCV-infected Patients Treatment-naive:HCVerso1

PHASE3

The aim of the study is to confirm efficacy of treatment for 16 and 24 week...

Status

Completed

Location

1241.20.00026 Boehringer Ingelheim Investigational Site

Start Date

2012-12

Trial ID

NCT01732796

Treatments Being Tested

Ribavirin (RBV)BI 201335 (Faldaprevir)Ribavirin (RBV)BI 207127 BI 201335 (Faldaprevir)Ribavirin (RBV)BI 207127 Faldaprevir (BI 201335)BI 207127

Thorough QT Study to Evaluate the Effects of BI 207127 (Deleobuvir) Combined With Faldaprevir on Cardiac Safety Parameters in Healthy Subjects.

PHASE1

The objective of this study is to evaluate the effect of multiple doses of ...

Status

Completed

Location

1241.40.1 Boehringer Ingelheim Investigational Site

Start Date

2013-10

Trial ID

NCT01965431

Treatments Being Tested

BI 207127 BI 207127 placebo Faldaprevir placebo Faldaprevir Moxifloxacin (Avalox®)

Safety, Antiviral Effect and PK of BI 207127 + BI 201335 +/- RBV for 4 up to 40 Weeks in Patients With Chronic HCV Genotype 1 Infection

PHASE2

The substances BI 201335 and BI 207127 are being developed for the treatmen...

Status

Completed

Location

1241.21.0003 Boehringer Ingelheim Investigational Site

Start Date

2010-05

Trial ID

NCT01132313

Drug Drug Interaction Study Between BI 201335 and BI 207127 in Chronic Hepatitis C Infected Patients

PHASE1

To evaluate the drug-drug interactions between BI 201335 and BI 207127 as w...

Status

Completed

Location

1241.27.0006 Boehringer Ingelheim Investigational Site

Start Date

2012-04

Trial ID

NCT01525628

Multiple Doses of BI 207127 NA, BI 201335 NA Followed by the Combination of BI 207127 NA and BI 201335 NA in Healthy Male Volunteers

PHASE1

Study to investigate the pharmacokinetic drug-drug interaction potential of...

Status

Terminated

Location

Multiple Locations

Start Date

2009-07

Trial ID

NCT02182401

Treatments Being Tested

BI 207127 NA BI 201335 NA Midazolam Tolbutamide

Safety, Tolerability and Pharmacokinetics of Different Multiple Doses of BI 207127 BID and Multiple Doses of BI 207127 Combined With Faldaprevir in Healthy Male and Female Subjects

PHASE1

The objective of the current trial is to evaluate safety, tolerability and ...

Status

Completed

Location

1241.35.1 Boehringer Ingelheim Investigational Site

Start Date

2012-11

Trial ID

NCT01737996

Treatments Being Tested

BI 207127 + faldaprevir

Previous Next